Multi-item joint inspection reagent card for inflammation detection

By designing a number of joint detection reagent cards, including IL-10, CRP/hs-CRP, PCT, IL-6, SAA indicators, and using a raised raised structure, the sensitivity and specificity of inflammation detection in the prior art are insufficient. The problem has achieved rapid and accurate multi-index testing, which is suitable for use in outpatient and emergency clinics and primary medical institutions.

CN221946017UActive Publication Date: 2024-11-01SUZHOU KUIKTAI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202323627928.6
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2024-11-01
Estimated Expiration
2033-12-29

AI Technical Summary

Technical Problem

The existing inflammation detection reagent cards have poor sensitivity and specificity. Single biomarkers cannot fully and accurately evaluate the inflammatory state. The multi-index detection reagent cards rarely contain IL-10 indicators, making it impossible to distinguish patients with inflammatory disorders and high inflammatory states. , the accuracy of the test results is affected by the sample surge.

Method used

Design a multi-item joint detection reagent card, including four indicators: IL-10, CRP/hs-CRP, PCT, IL-6, and SAA. The raised raised structure is used to block the sample surge. The test strips are divided into multiple cavity bodies The port is designed to improve detection accuracy and is suitable for use in hospital outpatient and emergency departments and primary medical institutions.

Benefits of technology

It improves the accuracy and specificity of inflammation detection, can conduct quantitative testing simultaneously within 15 minutes, and is suitable for use in hospital outpatient and emergency departments and primary medical institutions, reducing testing time and improving the accuracy of disease prognosis and labeling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN221946017U_ABST
    Figure CN221946017U_ABST
Patent Text Reader

Abstract

The utility model discloses a multi-item joint inspection reagent card for inflammation detection, at least three indexes comprise an IL-10 index and at least two indexes of CRP / hs-CRP, PCT, IL-6 and SAA, the reagent card comprises a shell and a test strip, the shell is provided with a sample adding port, the peripheral wall of the upper end of the sample adding port is provided with a heightening protrusion which protrudes and extends outwards, and the heightening protrusion is provided with a through hole. The heightening protrusion extends downwards into the shell and divides an inner cavity of the shell into a first cavity body and a second cavity body, the first cavity body is located under the sample adding opening and serves as a sample adding groove, and a through opening which is communicated with the first cavity body and the second cavity body and is used for a test strip to penetrate through in a bent mode is transversely formed in the protrusion; and the position of the through hole is higher than the bottom surfaces of the first cavity and the second cavity. The IL-10 index is combined with other indexes, so that multi-item joint detection of inflammation is realized, and the disease prognosis and disease marking accuracy can be improved. The heightening protrusion can prevent the sample from directly surging to the detection pad from the sample pad and the combination pad.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of biotechnology diagnosis, in particular to a multiple joint detection reagent card for inflammation detection. Background Art

[0002] Recently, increasing attention has focused on the contribution of inflammatory processes to the pathogenesis of atherosclerotic disease. The Physicians’ Health Study showed that low levels of systemic inflammatory markers, such as elevated C-reactive protein (CRP), can predict cardiovascular events in healthy men. The pathogenic link between inflammation and atherosclerosis appears to be of the monocyte / macrophage type. These cells produce proinflammatory cytokines that induce the liver to synthesize acute phase proteins, including CRP. On the other hand, these cells infiltrate atherosclerotic plaques, differentiate into tissue macrophages and foam cells, and attract more leukocytes through their cytokines. The more active these cells are, the faster the growth of atherosclerotic lesions. Although the progression and instability of vascular plaques are associated with detectable signs of inflammation, it is unclear whether inflammation promotes lesion growth or whether lesion instability leads to enhanced systemic cytokine release.

[0003] CRP / hs-CRP: C-reactive protein (CRP) is a non-specific marker of the emergency phase of systemic inflammatory response synthesized by the liver. Normally, the content in serum is extremely weak, but when the body has symptoms such as acute inflammation, trauma or infarction, CRP will increase significantly. High-sensitivity C-reactive protein (hs-CRP) is a type of C-reactive protein. It is an acute reaction protein with high physiological sensitivity. When the body faces bacterial and viral infections, cardiovascular diseases, and autoimmune diseases, the concentration of hs-CRP will increase. In recent years, the research and application of CRP and hs-CRP have become more and more extensive. CRP and hs-CRP have extremely high physiological sensitivity and low measurement concentration. Using them as judgment indicators can improve the accuracy of judgment in the process of inflammatory treatment and prognosis, which is of great significance for the treatment and restoration of patient health.

[0004] Interleukin 6 (IL-6) is a cytokine, one of the interleukins. IL-6 was found to be an inflammatory cytokine involved in B cell differentiation, and is a highly versatile cytokine with extremely strong biological activity. It participates in the body's immune response, hematopoiesis, and inflammatory response. The occurrence of many diseases is accompanied by changes in the body's IL-6. Under normal physiological conditions, the level of IL-6 in human body fluids is low, but when the body is in a pathological state, the secretion of IL-6 increases, triggering the release of various inflammatory factors, promoting the occurrence of inflammation, and causing tissue cell damage. Therefore, patients can be diagnosed and treated based on the concentration of IL-6. The level of IL-6 is closely related to health. The increase in IL-6 will not only affect physical health, but also social adaptation and mental health. Paying attention to the level of IL-6 is of great significance for predicting the development of the disease and subsequent treatment.

[0005] SAA: Serum amyloid A (SAA) is the precursor of tissue amyloid A and a sensitive positive acute phase reactant protein. For some diseases, such as viral infection, transplant rejection, coronary heart disease, etc., SAA is more sensitive than CRP and can provide better reference value for clinical practice. Clinically, when patients have fever, CRP is generally measured. When judging the cause of infection, it is generally believed that if CRP does not increase, it is a viral infection. Such a judgment is not reasonable and accurate. It is easy to attribute fever caused by other factors to viral infection, causing misdiagnosis. SAA is very sensitive to viral changes, so the combined detection of SAA and CRP makes clinical identification of bacterial and viral infections more reliable.

[0006] PCT: Procalcitonin (PCT) has the characteristics of rapid and accurate response to the body's infection and is an ideal biomarker. Serum PCT has high sensitivity and specificity in the diagnosis of infectious diseases. It can not only differentiate bacterial or non-bacterial infections at an early stage, but also has a positive correlation with the severity of the infection. In the whole course management of sepsis, the combined detection of IL-6 and PCT can complement each other and improve the accuracy of diagnosis. IL-6 has outstanding advantages in early warning and prognosis assessment, while PCT is very effective in auxiliary diagnosis and evaluation of antibiotic efficacy. The combined detection of IL-6 and PCT can avoid the error of single indicator in judging the infection category, improve the early diagnosis of infection, and help the clinic determine the treatment plan for patients in a timely manner, which has important clinical value.

[0007] IL-10: Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. High levels of IL-10 usually indicate that the patient is immunosuppressed, and often indicate the presence of inflammation or malignant tumor lesions in the body. IL-10 is an anti-inflammatory factor. Inflammatory factors in the acute phase reaction are reversely regulated by the anti-inflammatory cytokine IL-10. Increased levels of IL-10 can inhibit the secretion of biomarkers such as IL-6 and CRP. This leukocyte-derived factor limits the body's inflammatory response to pathogens. Abnormal early release of IL-10 can lead to immunosuppression, thereby causing inflammatory disorders. IL-10 is a good indicator of organ dysfunction caused by inflammatory disorders. In patients with sepsis, high levels of IL-10 are positively correlated with sepsis shock, multiple organ dysfunction syndrome, and even death. In patients with angina pectoris, there is no significant difference in IL-10 levels between patients with stable angina pectoris and healthy patients, while the level of CRP in acute coronary syndrome is increased and the level of IL-10 is decreased, which is positively correlated with the occurrence of malignant cardiovascular events. Studies have also shown that decreased IL-10 levels are associated with an increased risk of ischemic stroke. Therefore, compared with the sustained release of proinflammatory cytokines, immunosuppression caused by premature and excessive release of anti-inflammatory cytokines plays a more critical role in the process of progression from a high inflammatory state to dysregulated inflammation.

[0008] Existing inflammation detection reagent cards are generally single-index detection reagent cards with poor sensitivity and specificity. Moreover, as can be seen from the above, a single biomarker can only reflect part of the disease information from one aspect, and cannot comprehensively and accurately evaluate the type, pathology and pathophysiological changes of cerebral edema. In order to solve the defects of the above-mentioned technology, multi-index detection reagent cards are becoming more and more popular. Existing multi-index detection reagent cards for inflammation detection generally only include four indicators: IL-6, SAA, PCT, and CRP. IL-10 is rarely used as an indicator for combined inflammation detection. IL-6, SAA, PCT, and CRP are inflammatory factors. Although they can diagnose the patient's inflammatory state, they cannot distinguish between patients with inflammatory disorders and patients in a high inflammatory state. In addition, the existing multi-index detection reagent card generally includes a shell and a test strip arranged in the shell, and the shell is provided with a sample addition hole or sample addition port and an inspection window for adding samples, the inspection window corresponds to the top of the test pad of the test strip and is hollow, and the sample addition hole or sample addition port corresponds to the top of the sample pad of the test strip. Since the inspection window and the sample addition hole or sample addition port are in the same horizontal plane and there is a gap between the sample addition port and the test strip, when adding a liquid sample through the sample addition port or sample addition hole, the liquid sample may flow directly from the top of the sample pad to the inspection window and onto the test pad, or flow directly from the sample pad and the binding pad to the test pad through the gap, which will have a certain impact on the accuracy of the test results. Therefore, it is necessary to design a new multi-inspection reagent card that improves the accuracy and specificity of inflammation detection. Utility Model Content

[0009] In view of at least one of the above-mentioned technical problems, the utility model aims to provide a multiple combined test reagent card for inflammation detection.

[0010] The technical solution of the utility model is:

[0011] The utility model aims to provide a multiple joint test reagent card for inflammation detection, wherein the multiple indicators include at least three detection indicators, wherein the at least three indicators include an IL-10 indicator and at least two indicators among four indicators of CRP / hs-CRP, PCT, IL-6 and SAA, wherein the reagent card includes a shell and a test strip arranged in an inner cavity of the shell, wherein a sample addition port is provided on the shell, and a peripheral wall at the upper end of the sample addition port is provided with a heightened protrusion protruding and extending outward, wherein the heightened protrusion extends downward into the shell and divides the inner cavity of the shell into a first cavity and a second cavity, wherein a portion of the test strip is located in the first cavity and another portion is located in the second cavity, wherein the first cavity is located directly below the sample addition port and is implemented as a sample addition groove, wherein a through opening connecting the first cavity and the second cavity and for the test strip to be bent and passed through is horizontally provided on the protrusion, and the position of the through opening is higher than the bottom surfaces of the first cavity and the second cavity.

[0012] Preferably, the multiple combined test reagent card includes five indicators: CRP / hs-CRP, PCT, IL-6, SAA, and IL-10.

[0013] Preferably, the height of the through opening is 2 to 5 times the thickness of the test strip.

[0014] Preferably, the housing includes a flat bottom plate and a cover-shaped outer shell buckled on the bottom plate.

[0015] Preferably, the test paper strip comprises a first test paper portion arranged in the first cavity, a second test paper portion arranged in the second cavity and a third test paper portion passing through the through opening, the first test paper portion is located no higher than the through opening and when the sample is added, the sample at least partially covers the first test paper portion, the second test paper portion is horizontally fixed on the bottom plate, the third test paper portion is in an inverted U shape and the angles between the third test paper portion and the first test paper portion and the second test paper portion are both greater than 90° and less than 180°.

[0016] Preferably, a vertically protruding limit card is further provided on the bottom plate in the second cavity, and an end of the second test paper portion away from the third test paper portion abuts against the limit card.

[0017] Preferably, the protrusion comprises an upper protrusion and a lower protrusion which are opposite to each other and spaced apart from each other, and a top end surface of the upper protrusion is higher than a top surface of the shell.

[0018] Preferably, the number of the test strips is any one from one to five, and one to five inspection windows are opened on the top surface of the housing corresponding to the second cavity.

[0019] Preferably, any of the test strips comprises a sample pad, a blood filter pad, a binding pad, a detection pad and a sample suction pad stacked in sequence on the bottom plate, and the sample pad is located on the projection of the sample injection port on the bottom plate.

[0020] Preferably, when the number of the test strips is two to five, all the test strips share one sample addition pad and the blood filter pad is fan-shaped and scattered.

[0021] Compared with the prior art, the advantages of the utility model are:

[0022] The utility model of the multi-indicator joint test reagent card for inflammation detection adopts the IL-10 index and combines other indexes to realize the multi-indicator joint test of inflammation, which can improve the accuracy of disease prognosis and disease markers, and the multi-indicator joint test can save the detection time, and can simultaneously perform quantitative detection of the above five indicators within 15 minutes, with accurate results, which is suitable for use in hospital outpatient and emergency departments and primary medical institutions. By setting the raised protrusion, the sample can be blocked from flowing directly from the sample pad and the binding pad to the detection pad, and the detection accuracy is greatly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The utility model is further described below in conjunction with the accompanying drawings and embodiments:

[0024] Figure 1 This is a schematic diagram of the three-dimensional structure of a multiple-test reagent card for inflammation detection according to an embodiment of the utility model;

[0025] Figure 2 This is a schematic diagram of the cross-sectional structure of a multiple combined test reagent card for inflammation detection according to an embodiment of the utility model;

[0026] Figure 3 The schematic diagram of the top view of the outer shell is omitted for the multiple combined test reagent card for inflammation detection (there are five detection indicators and five test strips sharing one sample pad) according to the embodiment of the utility model.

[0027] Among them: 1. Shell; 11. Bottom plate; 12. Outer shell; 13. First cavity; 14. Second cavity; 2. Inspection window; 3. Sample loading port; 4. Heightening protrusion; 41. Lower protrusion; 42. Upper protrusion; 5. Limiting card; 6. Test strip; 61. Sample loading pad; 62. Blood filter pad; 63. Binding pad; 64. Detection pad; 65. Detection line; 66. Quality control line; 67. Sample suction pad. DETAILED DESCRIPTION

[0028] In order to make the purpose, technical solution and advantages of the utility model clearer, the utility model is further described in detail below in combination with specific implementation methods and with reference to the accompanying drawings. It should be understood that these descriptions are only exemplary and are not intended to limit the scope of the utility model. In addition, in the following description, the description of well-known structures and technologies is omitted to avoid unnecessary confusion of the concept of the utility model.

[0029] See also Figures 1 to 3 , a multi-indicator joint test reagent card for inflammation detection in an embodiment of the utility model, the multi-indicator includes five indicators: CRP / hs-CRP, PCT, IL-6, SAA, and IL-10. It should be noted that, as described in the background technology, CRP and hs-CRP are generally used in combination, so CRP and hs-CRP are used as an indicator in the embodiment of the utility model. It should also be noted that the multi-indicator joint test reagent card in the embodiment of the present invention does not necessarily need to include all five indicators. Exemplarily, the multi-indicators of the multi-indicator joint test reagent card in the embodiment of the utility model include at least three indicators, and the at least three indicators include the IL-10 indicator and at least two of the remaining four indicators (CRP / hs-CRP, PCT, IL-6, SAA). The reagent card includes a housing 1 and a test strip 6 arranged in the housing 1. The shell 1 is provided with a sample addition port 3, and a raised protrusion 4 is provided on the upper periphery of the sample addition port 3. The lower end of the raised protrusion 4 extends into the inner cavity of the shell 1 and divides the inner cavity of the shell 1 into a first cavity 13 and a second cavity 14. The first cavity 13 is located directly below the sample addition port 3 and is implemented as a sample addition slot. The raised protrusion 4 is provided with a through hole (not marked) that connects the first cavity 13 and the second cavity 14 laterally. The through hole is provided so that a part of the test strip 6 is in the first cavity 13 and the other part is in the second cavity 14 through the through hole. In addition, the position of the through hole is higher than the bottom surface of the first cavity 13 and the second cavity 14, so that the test strip 6 can be bent through the through hole. The utility model can prevent the sample from flowing directly from the sample pad and the binding pad 63 to the detection pad 64 through the inspection window 2 and the gap on the shell 12 by providing the raised protrusion 4. The detection reagent card of the embodiment of the utility model adopts the IL-10 index and combines other indexes to realize multiple joint tests, which can improve the accuracy of disease prognosis and disease markers, and the multi-index joint test can save detection time. The reagent can simultaneously perform quantitative detection of the above five indexes within 15 minutes, with simple operation, high sensitivity, strong specificity and accurate results. It is suitable for use in hospital outpatient and emergency departments and primary medical institutions.

[0030] According to some preferred embodiments of the present invention, Figure 2As shown, the heightened protrusion 4 includes an upper protrusion 42 and a lower protrusion 41 which are opposite to each other and spaced apart from each other, and the space between the upper protrusion 42 and the lower protrusion 41 forms a through opening. Due to the setting of the heightened protrusion 4, the test strip 6 is bent in the housing 1, and the bent test strip 6 may affect the capillary diffusion effect. Therefore, in order to solve this problem, the design of the through opening in the embodiment of the utility model needs to meet the requirements of the test strip 6 passing through, that is, the height of the through opening is greater than the thickness of the test strip 6, and further optimization is required to make the test strip 6 produce obvious folds to affect the capillary diffusion effect. Specifically, the applicant has found through research that the height of the through opening is 2 to 5 times the thickness of the test strip 6, which meets the requirements of the test strip 6 passing through smoothly and does not produce obvious folds to affect the capillary diffusion effect of the test strip 6.

[0031] According to some preferred embodiments of the present invention, Figure 2 As shown, for the housing 1, it includes a flat bottom plate 11 and a cover-shaped outer shell 12. An inner cavity is defined between the top surface of the outer shell 12 and the bottom plate 11. The test strip 6 includes a first test paper part, a third test paper part and a second test paper part from right to left as shown in the figure. The first test paper part is shorter in length and is arranged in an inclined shape in the first cavity, and the right end abuts on the plate body at the bottom end of the first cavity, and the left end has a gap with the plate body at the bottom end of the first cavity, which can reduce the influence of tossing on the capillary diffusion effect. The height of the first test paper part is not higher than the through-port, so as to prevent the sample from flowing directly onto the detection pad 64 through the gap at the through-port. The second test paper part is longer in length and is horizontally fixed on the bottom plate 11 at the bottom end of the second cavity. The third test paper part includes three sections and forms an inverted U shape. In order to avoid obvious creases affecting the capillary diffusion effect, the angle between the third test paper part and the second test paper part should be greater than 90° and less than 180°. Similarly, the angle between the first test paper part and the third test paper part should also be greater than 90° and less than 180°.

[0032] According to some preferred embodiments of the present invention, Figure 2 As shown, in order to facilitate the fixation of the test strip 6, a vertically protruding limit card 5 is also provided on the bottom plate 11 in the second cavity, and the end of the second test paper part away from the third test paper part, that is, the left end of the second test paper part as shown in the figure, abuts against the limit card 5. It can ensure that the test strip 6 is installed in a suitable position. The specific structure of the limit card 5 is not described or limited, such as the existing conventional pressure block or clamping block structure, or the limit card 5 is directly a vertical block, and a limit card 5 groove is opened on the side facing the test strip 6.

[0033] According to some preferred embodiments of the present invention, Figures 1 to 3 As shown, the profile of the sample loading slot is not limited to Figure 3The circle shown may also be other geometric shapes such as regular polygons, for example, regular triangles, squares, regular pentagons, and the like. In the embodiment of the utility model, the number of test strips 6 is any one of one to five, that is, the number of test strips 6 can be one, two, three, four, or five. The specific number depends on the number of detection indicators. When the number of detection indicators is three, the number of test strips 6 can be one, two, or three. When the number of detection indicators is four, the number of test strips 6 can be one, two, three, or four. When the number of detection indicators is five, the number of test strips 6 can be one, two, three, four, or five. When the number of test strips 6 is two to five, all test strips 6 can be as follows. Figure 3 As shown, they are arranged on the same side of the sample loading slot, or they can be arranged in a divergent manner around the sample loading slot. Figure 3 As shown, the top view of the sample loading slot is circular, and the number of detection indicators is five, that is, including all the above five indicators. The number of test strips 6 is five, and the five test strips 6 share a sample pad and are arranged in a fan-shaped scattered shape on the same side of the sample loading slot.

[0034] According to some preferred embodiments of the present invention, Figure 1 As shown, one to five inspection windows 2 are provided on the top surface of the housing 12 corresponding to the second cavity. The number of the inspection windows 2 is determined according to the number of the test strips 6. As an optional embodiment, no matter how many test strips 6 there are, the number of the inspection windows 2 is one, that is, all the test strips 6 share one inspection window 2. This can save processing steps and difficulty, and reduce processing costs.

[0035] According to some preferred embodiments of the present invention, Figure 2As shown, for the test strip 6, any test strip 6 includes a sample pad, a blood filter pad 62, a binding pad 63, a detection pad 64 and a sample suction pad 67 which are stacked and fixed on the top surface of the bottom plate 11 in sequence. The sample pad is arranged on the first test paper part, the blood filter pad 62 is arranged on the third test paper part, and the binding pad 63, the detection pad 64 and the sample suction pad 67 are all arranged on the second test paper part. In other words, the sample pad is located on the projection of the sample addition port 3 on the bottom plate 11. Specifically, when installing the test strip 6, one end of the sample addition pad 61 of the test strip 6 is slightly bent downward or allowed to droop naturally in the sample addition slot. After adding the sample liquid to the sample addition slot, the test strip 6 can move the sample liquid from one side of the sample pad to the side of the binding pad 63 and the detection pad 64 under the capillary suction of the sample suction pad 67 for detection and analysis. It should be noted that the conjugate pad 63 is coated with a fluorescent antibody coating of five indicators, namely, a specific detection antibody coating of five indicators, namely, time-resolved fluorescent microspheres or quantum dot microspheres. The detection pad 64 is provided with a detection line 65 and a quality control line 66, and the number of the detection lines 65 depends on the number of the test strips 6 or the detection indicators. Specifically, when the number of detection indicators is three, four or five and the number of test strips 6 is one, the number of detection lines 65 of the detection pad 64 is three, four or five. When the number of detection indicators is three and the number of test strips 6 is two, the number of detection lines 65 on the detection pad 64 of one test strip 6 is one or two, and the number of detection lines 65 on the detection pad 64 of the other test strip 6 is two or three. When the number of detection indicators is four and the number of test strips 6 is two or three, the number of detection lines 65 of the detection pad 64 of one test strip 6 is one, and the number of detection lines 65 of the detection pad 64 on the remaining test strips 6 is three, or the number of detection lines 65 of the detection pad 64 of two test strips 6 is one, and the number of detection lines 65 of the detection pad 64 of the other test strip 6 is two. Similarly, when the number of detection indicators is five and the number of test strips 6 is two or three or four, it will not be repeated. For the detection line 65, it is coated with a specific capture antibody corresponding to the detection indicator. The quality control line 66 is coated with a hapten or antibody that can bind to the specific detection antibody. No specific limitation or description is made. It should be noted that the CRP / hs-CRP, PCT, IL-6, SAA, IL-10 specific capture antibodies used to coat the detection line 65 can be polyclonal antibodies or monoclonal antibodies. The coating of the quality control line 66 may be a hapten, or may be goat anti-mouse IgG, goat anti-chicken IgY or goat anti-rabbit IgG. The specific detection antibody may be a polyclonal antibody or a monoclonal antibody. The specific detection antibody is coupled to a fluorescent microsphere. The fluorescent microsphere used for coupling is a polystyrene microsphere filled with a chelate of a lanthanide element selected from one of europium, terbium, samarium, neodymium or dysprosium.

[0036] For multiple indicators, there can be three indicators, specifically CRP / hs-CRP, IL-6, IL-10, or CRP / hs-CRP, PCT, IL-10, or CRP / hs-CRP, SAA, IL-10, or IL-6, PCT, IL-10, or IL-6, SAA, IL-10. It can also be four indicators, specifically, CRP / hs-CRP, PCT, IL-6, IL-10, etc. So there are five indicators, that is, all the above indicators, CRP / hs-CRP, PCT, IL-6, SAA, IL-10.

[0037] Preparation of the multi-link detection reagent card of the utility model embodiment:

[0038] The sample pad, the blood filter pad 62, the conjugate pad 63, the detection pad 64 and the sample suction pad 67 are arranged according to Figure 3 As shown, the test strips 6 are fixed to the bottom plate 11 in sequence to obtain a test strip 6 for detecting a blood sample, and then the test strip 6 is assembled with the housing 12 to obtain a multiple test reagent for inflammation detection.

[0039] How to use this test card:

[0040] Step 1: Equilibrate the test reagent card and sample to room temperature, take out the reagent card and lay it flat;

[0041] Step 2: Take 75ul of serum, plasma or whole blood sample and add it to a tube of buffer, mix thoroughly, and vertically drip 75ul of the mixture into the sample slot and sample port 3. Be careful not to inhale bubbles when sampling;

[0042] Step 3: The test can be performed in two modes: automatic test or instant test. Automatic test: insert the reagent card into the corresponding instrument's carrier, press the test button, and the instrument will automatically scan and analyze the reagent card;

[0043] Instant test: After the reagent card is placed at room temperature for 15 minutes, insert it into the carrier of the corresponding instrument and click on the instant test.

[0044] The utility model can use serum, plasma or whole blood as detection samples, has strong versatility, and can simultaneously detect CRP / hs-CRP, PCT, IL-6, SAA, and IL-10, thereby doubling the detection efficiency and greatly reducing the workload and time required for marker detection of inflammatory-related diseases, quickly predicting the disease or evaluating the course of the disease, so that patients can receive more timely and targeted treatment.

[0045] It should be understood that the above specific embodiments of the present invention are only used to illustrate or explain the principles of the present invention, and do not constitute a limitation on the present invention. Therefore, any modifications, equivalent substitutions, improvements, etc. made without departing from the spirit and scope of the present invention should be included in the protection scope of the present invention. In addition, the claims attached to the present invention are intended to cover all changes and modifications that fall within the scope and boundaries of the attached claims, or the equivalent forms of such scope and boundaries.

Claims

1. A multiple-test reagent card for inflammation detection, characterized in that: The multiple indicators include at least three detection indicators, and the at least three indicators include the IL-10 indicator and at least two of the four indicators of CRP / hs-CRP, PCT, IL-6, and SAA. The reagent card includes a shell and a test strip arranged in the inner cavity of the shell, and the shell is provided with a sample addition port, and the upper end peripheral wall of the sample addition port is provided with an increased protrusion protruding outward, and the increased protrusion extends downward into the shell and divides the inner cavity of the shell into a first cavity and a second cavity. A part of the test strip is in the first cavity and the other part is in the second cavity. The first cavity is directly below the sample addition port and is implemented as a sample addition groove. A through hole is horizontally opened on the protrusion, which connects the first cavity and the second cavity and is provided for the test strip to bend and pass through, and the position of the through hole is higher than the bottom surface of the first cavity and the second cavity.

2. The multiple combined test reagent card for inflammation detection according to claim 1, characterized in that: The multiple joint test reagent card includes five indicators: CRP / hs-CRP, PCT, IL-6, SAA, and IL-10.

3. The multiple-test reagent card for inflammation detection according to claim 1 or 2, characterized in that: The height of the through hole is 2 to 5 times the thickness of the test strip.

4. The multiple combined test reagent card for inflammation detection according to claim 1 or 2, characterized in that: The shell comprises a flat bottom plate and a cover-shaped outer shell buckled on the bottom plate.

5. The multiple-test reagent card for inflammation detection according to claim 4, characterized in that: The test paper strip includes a first test paper portion arranged in the first cavity, a second test paper portion arranged in the second cavity, and a third test paper portion passing through the through opening, wherein the first test paper portion is located no higher than the through opening and when the sample is added, the sample at least partially covers the first test paper portion, the second test paper portion is horizontally fixed on the bottom plate, and the third test paper portion is in an inverted U shape and the angles between the third test paper portion and the first test paper portion and the second test paper portion are both greater than 90° and less than 180°.

6. The multiple-test reagent card for inflammation detection according to claim 5, characterized in that: A vertically protruding limit card is also provided on the bottom plate in the second cavity, and one end of the second test paper portion away from the third test paper portion abuts against the limit card.

7. The multiple combined test reagent card for inflammation detection according to claim 4, characterized in that: The protrusions include an upper protrusion and a lower protrusion that are opposite to each other and spaced apart from each other, and a top end surface of the upper protrusion is higher than a top surface of the shell.

8. The multiple combined test reagent card for inflammation detection according to claim 4, characterized in that: The number of the test strips is any one from one to five, and the top surface of the shell corresponding to the second cavity is provided with one to five inspection windows.

9. The multiple-test reagent card for inflammation detection according to claim 8, characterized in that: Any of the test strips comprises a sample pad, a blood filter pad, a binding pad, a detection pad and a sample suction pad stacked in sequence on the bottom plate, and the sample pad is located on the projection of the sample injection port on the bottom plate.

10. The multiple combined test reagent card for inflammation detection according to claim 9, characterized in that: When the number of the test strips is two to five, all the test strips share one sample adding pad and the blood filtering pad is fan-shaped and scattered.